Orthopedics pedics - curasan Inc.
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Spine
pedics Trauma
entistry Orthopedics
Osteoarthritis Therapy Den
pine Dentistry Orthop
Spine Traum
Orthope
Literature List 2020CONTENT
CERASORB® & CERACELL®
Dentistry.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4–38
Orthopedics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39–46
Scientific Fundamentals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47–76
JEDER®
Dentistry.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78–80
Curavisc®
Orthopedics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82–87
stypro®
Dentistry.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89–91
Orthopedics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
General Surgery...................................................................................................................................... 93–94
Scientific Fundamentals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
Explanation
Abbrev.: Meaning:
M Material Scientific / Fundamental Research
P Preclinic / in-vitro and in-vivo study
DC Clinic – Dental / Oral and Maxillofacial Surgery
TC Clinic – Traumatology / Orthopedics
d Dentoalveolar and OMF surgery
t Trauma surgery
o Orthopedic surgery
s Spine surgery / neurosurgery
2CONTENT
CERASORB® & CERACELL®
Dentistry
2019. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2018. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2006. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2017. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2005. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2016. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 2004. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2015. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2003. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2013. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 2002. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2012. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 2001. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2011. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 2000. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2010. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 1999......................................................37
2009. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 1998......................................................38
2008. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 1997......................................................38
Orthopedics, Trauma & Spine
2017. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 2009. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
2016. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2015. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 2006. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
2014. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 2002. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
2013. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 2001. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
2012. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 1999. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
SF Scientific Fundamentals
Preclinic / in-vitro and in-vivo study 2003. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
2020. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 2002. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
2019. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 2001. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
2018. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 2000. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
2017. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
2016. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 Material Scientific / Fundamental Research
2015. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 2020. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
2014. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 2019. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
2013. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56 2009. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
2011. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59 2006. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
2010. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 2005. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
2009. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61 2004. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
2008. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
2006. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
2005. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
2004. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
3CERASORB® & CERACELL® – 2019
Year Legend Literature Products
DENTISTRY
2019 DC Duarte F, Ramos C (2019): CERASORB® M,
d Protocolo Implacure® – Tratamento descontaminante e regenera- Osgide®
tive da peri-implantite. [The Implacure® protocol – decontamina-
tion and regenerative treatment of peri-implantitis.]
O Jornal Dentistry 59, February 2019, online publication in Por-
tugese, Abstract in English.
Comment:
“The treatment of a peri-implantitis case with bone defect of
40% of the length of the implant involving the use of the
Implacure® Protocol in combination with a physical
decontamination technique, followed by bone regeneration
using CERASORB® M.”
2019 DC Foitzik J (2019): CERASORB®
d Minimalinvasiver Sinuslift nach JEDER – ein Erfahrungsbericht. Paste,
[Minimally invasive sinus lift according to JEDER – a case report.] JEDER® System
Implantologie Journal 12, 2019.
Comment:
“The article describes the experience with JEDER® System
for the transcrestal sinus lift in combination with CERASORB®
Paste in about 60 cases within 2 years. One case described in
more detail. On the basis of this experience, sinus floor
elevation according to JEDER® can be recommended without
restriction as a reliable minimally invasive method for bone
augmentation in the upper jaw side tooth area. No side
effects or complications are reported. A case of a multi-
chambered maxillary sinus in region 26 with a clear bony
septum and insufficient vertical bone for an implant insertion
is presented.”
2019 DC Palm F, Rupp J, Götz W (2019): CERASORB®
d Experiences with a collagen composite in socket preservation. Foam,
implants 2019, 4: 14-18. CERASORB® M,
stypro®
Comment:
“A split-mouth clinical study with 35 patients was designed
to evaluate the performance of CERASORB® Foam in socket
preservation procedures. As a comparative material, a
gelatine haemostatic sponge (stypro®, curasan) was chosen
owing to similarities in the application techniques of both
products. The publication presents two cases out of the
study; one case of a patient with after severe periodontal
disease affecting the bone and another case of alveolar ridge
preservation with five teeth extracted. The healing in the
CERASORB® Foam group was as good as the healing in the
stypro® group. Both materials stabilised the haematoma,
which was very good for the healing process. However, the
bone loss in the stypro® group was significantly higher than
in the CERASORB® Foam group.”
4CERASORB® & CERACELL® – 2018
Year Legend Literature Products
DENTISTRY
2018 DC Duarte F, Thomas G (2018): Peri-implantitis therapy. Using CERASORB® M
d resorbable bone replacement material. implants 4, 2018: 24-26.
Comment:
“Description of the authors’ preferred protocol of peri-
implantitis treatment protocol using a biomimetic bone
replacement material (CERASORB® M) and a resorbable
collagen membrane.”
2018 DC Lorenz J, Barbeck M, Kirkpatrick CJ, Sader R, Lerner H, CERASORB®
d Ghanaati S (2018): Injectable bone substitute material on the Paste
basis of β-TCP and hyaluronan achieves complete bone
regeneration while undergoing nearly complete degradation.
Int J Oral M
axillofac Implants. 2018 May/June;33(3):636–644.
doi: 10.11607/jomi.6026. Epub 2018 Mar 15.
Comment:
“The regenerative potential and pathways of a new injectable
bone substitute (IBS) material composed of beta-tricalcium
phosphate (β-TCP) and hyaluronan were investigated for its
application in alveolar bone regeneration within extraction
sockets. In the prospective study CERASORB® Paste was
implanted in 44 extraction sockets after removal of teeth. The
paste contributed to an osteoconductive tissue reaction
while undergoing a time-controlled degradation. Clinical and
radiological follow-up investigation of the implants inserted
in the regenerated area after at least one year revealed that
the paste contributed to a long-term stable implantation bed
for dental implants.” “The IBS was convincing with its
favorable handling and enabled the complete filling of the
extraction sockets, successful, stable, and effective
replacement of the extracted teeth.” “The bone substitute
material contributed to new bone formation and a stable
surrounding for dental implants with a favorable and gentle
tissue reaction and almost complete biomaterial degradation.”
CERASORB® & CERACELL® – 2017
Year Legend Literature Products
2017 DC Lerner H (2017): CERASORB®
d Augmentation and defect filling in oral surgery. A multicenter Paste,
non-interventional study. implants 2017, 2: 26–30. membranes,
Osgide®,
Comment:
PTFE
“The novel paste-like bone regeneration material
CERASORB® Paste, based on small β-TCP granules and a
hyaluronic acid matrix has proven its efficacy in the filling of
smaller jaw defects under daily practice conditions,
especially because of its good manageability.”
5CERASORB® & CERACELL® – 2017
Year Legend Literature Products
DENTISTRY
2017 DC Ludwig A, Thomas G (2017): A Clinical Comparison. ß-tricalcium CERASORB® M,
d phosphate vs hydroxyapatite ceramics. [Ein klinischer Vergleich. Osbone®
Einsatz von ß-Tricalciumphosphat versus Hydroxylapatitkeramik.]
implants 2017, 4: 38-41. Article in English. First published in:
Implantologie Journal 2016, 11: 36-39. Article in German.
Comment:
“β-TCP offers advantages in the filling of cysts where the
goal is called physiologic bone regeneration. For sinus-
lifting both materials are well suited. In combination with
lateral augmentation or in cases with bad bone quality (D3/
D4) and/or two-step procedures hydroxyapatite should be
preferred.”
2017 DC Miller RJ (2017): Vergleich von Knochenersatzmaterialien. CERASORB® M
d Risiken und Vorzüge synthetischer und boviner Materialien.
[Comparison of bone-graft substitutes. Risks and benefits of
synthetic and bovine derivate materials.] Implantologie Journal
2017, 1&2: 28-30. Article in German. First published in: implants
2016, 4: 30-32. Article in English.
Comment:
“CERASORB® M is highly resorbable and replaced by
autogenous bone at a rapid rate. Also, it provides a higher
stress bearing modulus from an increased density. Last but
not least, there is no foreign-body reaction and no risk of
transmitting prions – it is safe.”
2017 DC Schermer S (2017) From granules to foam. [Vom Granulat zum CERASORB® M,
d Foam. Die Entwicklung eines β-Tricalciumphosphat – Knochen CERASORB®
regenerationsmaterials in klinischen Beispielen.] implants 3, Foam,
2017: 28-32. Article in English. First published in: Dent Implantol Epi-Guide
2016, 20 (5): 302-309. Article in German.
Comment:
“The clinical examples show that β-TCP embedded in a
collagen matrix offers an easy application and protection of
the Schneiderian membrane in sinus-lift procedures.
CERASORB® Foam plays an important role in the
overwhelming number of augmentative indications by rapid
change to vital own bone by support of the collagen matrix.”
6CERASORB® & CERACELL® – 2016
Year Legend Literature Products
DENTISTRY
2016 DC Bilk D (2016): CERASORB®
d Alveolenmanagement – Vorgehen und Mehrwert für Praxis und Foam
Patient.
[Teethridge Management – Approach and Benefit for Practice and
Patient.]
Dent Implantol, 20, 4, 228–231 (2016). Article in German.
Comment:
“CERASORB® Foam has proven its efficacy in the
augmentation of a larger vestibular defect as well in sinus
augmentation and alveolar ridge preservation.”
2016 DC Blem G (2016): Bestimmung der relativen Kieferknochendichte CERASORB® M
d mittels digitalen Messverfahrens nach Defektauffüllungen mit
β-TCP unter Berücksichtigung der klinischen Verläufe. [Determi-
nation of the relative jawbone density by means of digital measur-
ing method after defect filling with β-TCP taking into account the
clinical course.] Dissertation, Medizinische Fakultät der
Georg-August-Universität zu Göttingen, Germany 2016: 1-87.
Text in German.
Comment:
“Retrospective determination of bone density after treatment
with β-TCP in 411 defect cases with the following
indications: root tip resections (n = 181), filling of alveolar
ridge defects for socket preservation (n = 47), osteotomies
(n = 34), cysts (n = 14) and augmentations in connection with
implants (n = 135). Relative bone density compared to the
surrounding healthy bone between 97% and 102% was
achieved in the four study groups (root tip resection
osteotomy, socket preservation, cysts) after five to eleven
months of follow-up. High absorption rate of β-TCP was
shown with the addition of autogenous spongiosa from the
implant drilling shaft. Demographic data such as age, gender
of the patient, localization of defects had no statistically
significant influence on the measurement results of relative
bone density, bone regeneration or complication rate.”
2016 DC Ludwig A, Thomas G (2016): CERASORB® M,
d Einsatz von β-Tricalciumphosphat versus Hydroxylapatitkeramik. Osbone®
Ein klinischer Vergleich. [On the Application of
β-Tricalciumphosphate versus Hydroxyapatite Ceramics.
A Clinical Comparison.]
Implantologie Journal 2016, 11: 36–39. Article in German.
Comment:
“β-TCP offers advantages in the filling of cysts where the
goal is called physiologic bone regeneration. For sinus-
lifting both materials are well suited. In combination with
lateral augmentation or in cases with bad bone quality (D3/
D4) and/or two-step procedures hydroxyapatite should be
preferred.”
7CERASORB® & CERACELL® – 2016
Year Legend Literature Products
DENTISTRY
2016 DC Miller RJ (2016): CERASORB® M
d Comparison of bone-graft substitutes. Risks and benefits of
synthetic and bovine derivate materials.
implants 2016, 4: 30–32.
Comment:
“CERASORB® M is highly resorbable and replaced by
autogenous bone at a rapid rate. Also it provides a higher
stress bearing modulus from an increased density. Last but
not least, there is no foreign-body reaction and no risk of
transmitting prions – it is safe.”
2016 DC Schermer S, Kumalic S (2016): CERASORB® M,
d Vom Granulat zum Foam. Die Entwicklung eines β-Tricalcium- CERASORB®
phosphat – Knochenregenerationsmaterials in klinischen Beispielen. Foam,
[From Granules to Foam. The Development of a β-Tricalcium- Epi-Guide
phosphate Bone Regeneration Material in Clinical Cases.]
Dent Implantol 2016, 20 (5): 302–309. Article in German.
Comment:
“The clinical examples show that β-TCP embedded in a
collagen matrix offers an easy application and protection of
the Schneiderian membrane in sinus-lift procedures.
CERASORB® Foam plays an important role in the
overwhelming number of augmentative indications by rapid
change to vital own bone by support of the collagen matrix.”
CERASORB® & CERACELL® – 2015
Year Legend Literature Products
2015 DC Lorenz J, Barbeck M, Schlee M, Lerner H, Teiler A, Sader R, CERASORB®
d Ghanaati S (2015): Anwendungsbeobachtung einer β-TCP- Paste
basierten Knochenersatzmaterialpaste.
[Observation Study of a bone substitute paste based on β-TCP.]
Implantologie Journal 2015: 6: 24–30. Article in German.
Comment:
“When placing dental implants three months after
augmentation a bony regenerated implant site was found,
which enabled a stable insertion of dental implants.”
8CERASORB® & CERACELL® – 2013
Year Legend Literature Products
DENTISTRY
2013 DC Daif ET (2013):Effect of a multiporous beta-tricalicum phosphate CERASORB® M
d on bone density around dental implants inserted into fresh ex-
traction sockets. J Oral Implantol. 2013 Jun;39(3):339-44. doi:
10.1563/AAID-JOI-D-11-00079. Epub 2011 Sep 26.
Comment:
“Twenty-eight patients (18 women and 10 men), indicated for
extraction of their lower premolars and insertion of
immediate dental implants, were included in this study. They
were randomly divided into two equal groups (14 patients
each). Group A received immediate dental implants without
any filling material around the implants, while group B
received a pure-phase multiporous β-TCP (CERASORB® M,
500–1000 μm) which was mixed with a sterile normal saline
and gently packed into the bone gaps around the implants. In
all cases, the width of bone defects at the coronal portion of
the implants was larger than 2 mm.” “The statistical analysis
of the collected data showed a significant increase in the
bone density measurements from 3 to 6 months only in
group B (PCERASORB® & CERACELL® – 2013
Year Legend Literature Products
DENTISTRY
2013 DC Rahpeyma A, Khajehahmadi S, Hosseini VR (2013): CERASORB®
d Lateral ridge split and immediate implant placement in moderately
resorbed alveolar ridges: How much is the added width?
Dent Res J (Isfahan). 2013 Sep; 10 (5): 602–608.
Comment:
“Twenty-five patients were managed with ridge splitting
technique. CERASORB® was used to fill the intercortical
space. The technique showed predictable outcomes. The
waiting time between surgery and beginning of
prosthodontic treatment could be reduced to 3 months.”
2013 DC Shalash MA, Rahman HA, Azim AA, Neemat AH, Hawary HE, CERASORB® M
d Nasry SA (2013): Evaluation of horizontal ridge augmentation
using beta tricalcium phosphate and demineralized bone matrix:
A comparative study. J Clin Exp Dent. 2013 Dec 1;5(5):e253-9.
doi: 10.4317/jced.51244. eCollection 2013 Dec 1.
Comment:
“Evaluation of the effectiveness of beta tricalcium phosphate
(β-TCP/CERASORB® M) alone compared to β-TCP and
Demineralized Bone Matrix (DBM) in regenerating localized
horizontal maxillary alveolar ridge deficiencies prior to
implant placement. 20 patients with horizontal maxillary
ridge deficiencies; initial ridge width of ≤ 5mm. There was a
statistically significant difference between the mean area
percentage of mineralized bone between both groups where
it was 40.1% (range: 27.76% – 66.29%) for group I and 68.96%
(range: 60.07% – 87.33%) for group II. Group II showed more
bone gain with a mean of 1.37 mm crestally and 2.44 mm
apically. This difference however was not statistically
significant.”
CERASORB® & CERACELL® – 2012
Year Legend Literature Products
2012 DC Modina T (2012): CERASORB®
d Intellectual system of modern β-TCP materials and its role in
periodontal surgery.
Poster No. P0189. Poster presentation on EUROPERIO 7,
7th Conference of the European Federation of Periodontology,
Vienna/Austria 6–9 June 2012. Abstract.
Comment:
“Longstanding multicentre scientific and practical
experience with CERASORB® gives grounds to its
consideration as one of the materials having the intellectual
and informative qualities (“life crystals”) that are capable of
precipitating the bone regeneration process.”
10CERASORB® & CERACELL® – 2012
Year Legend Literature Products
DENTISTRY
2012 DC Kühl S, Götz H, Brochhausen C, Jakse N, Filippi A, d’Hoedt B, CERASORB®
d Kreisler M (2012): The influence of substitute materials on bone
density after maxillary sinus augmentation: amicrocomputed to-
mography study. Int J Oral Maxillofac Implants. 2012 Nov-
Dec;27(6):1541-6.
Comment:
“The study evaluates whether adding bone substitute
materials to autogenous particulated bone (PAB) might have
an effect on the density of the grafted bone after maxillary
sinus augmentation. Thirty healthy patients undergoing
lateral antrostomy were included. Sinuses were augmented
at random with PAB (n = 10) (control group); a mixture of
PAB and beta-tricalcium phosphate (β-TCP (CERASORB®
1000 – 2000 μm)) (n = 10) (experimental group); or a mixture
of PAB, β-TCP, and hydroxyapatite (HA) (Straumann®
BoneCeramicTM, 500 to 1,000 pm) (n = 10) (experimental
group). A sample of each graft material was obtained at time
of maxillary sinus augmentation, and microcomputed
tomography (μ-CT) analyses were performed at baseline and
after 5 months. All groups showed increasing density values
after a healing time of 5 months. Because of a high dropout
rate, the sample size was too small to compare the groups
statistically.”
CERASORB® & CERACELL® – 2011
Year Legend Literature Products
2011 DC Khatiblou F (2011): Histologic and histometric evaluation of CERASORB®
d bovine cancellous bone and beta-tricalcium phosphate 45 months
after grafting in maxillary sinus. J Oral Implantol.
2011 Dec;37(6):727-33. doi: 10.1563/AAID-JOI-D-10-00093.
Epub 2010 Oct 13.
Comment:
“Single case description comparing CERASORB® and bovine
cancellous bone (BCB) chips in sinus lift and 45 months
follow-up with biopsies taken. Both β-TCP and BCB were
completely resorbed and replaced by new bone 45 months
after grafting. Percentage of calcified bone, marrow and
connective tissue were almost the same.”
11CERASORB® & CERACELL® – 2010
Year Legend Literature Products
DENTISTRY
2010 DC Jang HY, Kim HC, Lee SC, Lee JY (2010): Choice of graft materi- CERASORB®,
d al in relation to maxillary sinus width in internal sinus floor aug- PRP
mentation. J Oral Maxillofac Surg. 2010 Aug;68(8):1859-68. doi:
10.1016/j.joms.2009.09.093. Epub 2010 May 26.
Comment:
“In a total of 57 patients, 100 implants were placed by 3
different sinus floor augmentation techniques (lateral
approach technique, osteotome technique, sinus drill and
osteotome technique). Postoperative cone-beam CT (CBCT)
scans were performed and the arrival distance of grafts from
lateral wall to medial wall at the apical end level of the
implant in the maxillary sinus was measured. Autogenous
bone versus CERASORB®.” “In the internal sinus floor
augmentation, grafting materials with solely osteoconductive
potential are to be used for narrow sinuses. For large
sinuses, autogenous bone with osteogenic potential should
be used; alternatively, the reflection of the medial wall by the
lateral window technique is recommended.”
2010 DC Kebernik M, Palm F (2010): CERASORB® M
d Die Sinusbodenelevation und ihre Risiken.
[Sinus floor augmentation and its risks.]
Oralchirurgie Journal 2010, 1: 14–18. Article in German.
Comment:
“The application of autologous bone alone gives no
advantage compared to a mixture of bone and bone
regeneration material (CERASORB® M) regarding implant
survival rate.”
2010 DC Soleymani Shayeste Y, Khorsand A, Mahvidy Zade S, Nasiri M CERASORB®
d (2010):
Clinical and radiographic evaluation of pure beta-tricalcium
phosphate and autogenous bone graft in treatment of two to
three-walled periodontal defects. [Abstract in English].
J Dent Med-Tehran University of Medical Sciences 2010; 23 (3):
183–190.
Comment:
“The aim of this double blind study was to compare the
effect of CERASORB® with autogenous bone graft (A.B.G) in
the treatment of 24 two to three wall periodontal defects with
baseline and 3-month, 6-month and one-year follow up
evaluations. Treatment with CERASORB® compared to A.B.G
produced the same results of improvement. Thus, the use of
CERASORB® can be suggested in treatment of infrabony
periodontal defects.”
12CERASORB® & CERACELL® – 2009
Year Legend Literature Products
DENTISTRY
2009 DC Elmohandes WA (2009): CERASORB® M
d Evaluation of CERASORB® M as a bone graft used for sinus lift
and dental implant installation. Abstract No. O10.12 in: Abstracts
of the 19th International Conference on Oral and Maxillofacial
Surgery, Shanghai, China, 23–27 May, 2009.
International Journal of Oral and Maxillofacial Surgery, May 2009,
38 (5): S. 499 von 397–608.
Comment:
“The X-ray revealed complete or nearly complete
degradation of the beta-tricalcium phosphate granules with
concurrent bone substitution in the majority of cases in
12 months post grafting. The implants showed good stability
12 months after installation.”
2009 DC Harnack L, Boedeker RH, Kurtulus I, Boehm S, Gonzales J, CERASORB®,
d Meyle J (2009): PRP
Use of platelet-rich plasma in periodontal surgery – a prospective
randomised double blind clinical trial. Clin Oral Investig.
2009 Jun; 13 (2): 179–187.
Comment:
“22 patients showing contralateral intrabony defects were
treated with β-TCP CERASORB® alone or in combination with
PRP. β-TCP is a satisfactory graft material in periodontal
surgery, even without PRP.”
2009 DC Horowitz RA, Mazor Z, Miller RJ, Krauser J, Prasad HS, Rohrer CERASORB®,
d MD (2009): barriers,
Clinical evaluation of alveolar ridge preservation with a membranes,
β-tricalcium phosphate socket graft. Compendium; 2009 Dec; PTFE
30(9): 588–603.
Comment:
“Clinical measurements showed preservation of alveolar
width, and histologic analysis demonstrated both resorption
of β-TCP (CERASORB®) and conversion to vital alveolar
bone. These characteristics make this graft material ideal for
use after tooth extraction in conventional and implant
dentistry.”
2009 DC Horowitz RA, Rohrer MD, Prasad HS, Mazor Z (2009): CERASORB® M,
d Enhancing Extraction – Socket Therapy. The Journal of Implant & membranes,
Advanced Clinical Dentistry. 2009 Sept; 1 (6): 47–59. Epi-Guide,
PTFE
Comment:
“The predictable formation of vital bone in the extraction
sockets treated with β-TCP of this and other studies has led
to 100% success rates in implant placement and loading.”
13CERASORB® & CERACELL® – 2009
Year Legend Literature Products
DENTISTRY
2009 DC Meyer C, Chatelain B, Benarroch M, Garnie JF, Ricbourg B, CERASORB®,
d Camponovo T (2009): PRP
Greffes sinusiennes massives par phosphate tricalcique.
Résultats à long terme.
[Massive sinus-lift procedures with β-tricalcium phosphate:
Long-term results].
Rev Stomatol Chir Maxillofac. 2009 Apr; 110 (2): 69–75. Epub
2009 Jan 25. Article in French.
Comment:
“In 20 patients a total number of 33 sinus lift procedures by
means of β-TCP CERASORB® were performed. The mean
postoperative follow-up was 4.5 years. The implant success
rate was 97.6%.”
2009 DC Nitsch A, Gruber R, Daevers INC, Patyk A, Merten HA (2009): CERASORB®,
d Sinusbodenaugmentation mit β-Tricalciumphosphat und PRP
plättchenreichem Plasma.
[Sinus floor elevation with β-tricalcium phosphate and Platelet
Rich Plasma.]
ZWR 2009, 118 (6): 276–287. Article in German.
Comment:
“In 29 patients an augmentation of sinus maxillaris with
β-TCP or β-TCP and PRP was performed. The
histomorphologic findings showed a progredient hydrolytic
β-TCP degradation and cellular resorption of the ceramic
fragments. The addition of PRP showed no difference.”
2009 DC Tetsch J, Tetsch P, Lysek DA (2010): Long-term results after later- CERASORB®
d al and osteotome technique sinus floor elevation: a retrospective
analysis of 2190 implants over a time period of 15 years. Clin
Oral Implants Res. 2010 May;21(5):497-503. doi:
10.1111/j.1600-0501.2008.01661.x.
Comment:
“Retrospective analysis of 2190 implants over a time period
of 15 years comparing lateral and osteotome technique in
sinus floor elevation. 1207 implants (461 patients) were
placed into sites, in which the sinus was augmented using
the lateral approach (LSFE), and 983 implants (522 patients)
in sites augmented with the osteotome technique. Bovine
bone mineral (n = 1217), β-tricalcium phosphate (n = 126). In
12% of cases CERASORB® was used (when patients were
refusing xenogenic material). The implant survival rate with
respect to the augmentation material was given as 97.4%
after 170 months for the bovine bone mineral (Bio-Oss) and
94.1% for β-tricalcium phosphate (TCP) (CERASORB®) after
91 months (but less patients). Looking at the implant survival
rate, no significant difference could be observed statistically
zbetween the two materials.”
14CERASORB® & CERACELL® – 2009
Year Legend Literature Products
DENTISTRY
2009 DC Waluga R (2009): CERASORB®,
d Erfolgsbewertung der klinischen Anwendung von CERASORB® M
β-Trikalziumphosphat zur alloplastischen Rekonstruktion
knöcherner Defekte im Kiefer- und Gesichtsbereich.
[Clinical evaluation of β-tricalciumphosphate in the treatment of
maxillofacial bone defects.]
Dissertation, Medizinische Fakultät Charité – Universitätsmedizin
Berlin, 2009: 1–65. Text in German.
Comment:
“A good clinical result can be achieved in traumatic defects
up to 4 cm³ in combination with stable osteosynthesis and in
cystic defects up to 4 cm³ with sufficient soft tissue closure,
even without the admixture of autologous spongiosa.”
CERASORB® & CERACELL® – 2008
Year Legend Literature Products
2008 DC Beyrle B (2008): CERASORB®,
d Die simultane Implantation mit Sinusliftoperation bei reduziertem (membrane),
Knochenangebot – eine retrospektive, klinische Studie. (Epi-Guide)
[Simultaneous implantation with sinus lift operation in reduced
bone – a retrospective, clinical study.]
Dissertation, Department für Zahnheilkunde der Medizinischen
Fakultät der Universität Ulm, 2008: 1–111. Text in German.
Comment:
“The augmentation material CERASORB® showed very good
results regarding the remodelling of the implant. The
augmentation of the sinus with CERASORB® is to be
preferred instead of the use as admixture or the sole use of
autologous bone chips.”
2008 DC Knabe C, Koch C, Rack A, Stiller M (2008): CERASORB®,
d Effect of beta-tricalcium phosphate particles with varying porosity CERASORB® M
on osteogenesis after sinus floor augmentation in humans.
Biomaterials 2008, 29: 2249–2258.
Comment:
“2 groups of 10 patients each were treated with CERASORB®
and CERASORB® M. After 6 months, bone formation and
matrix mineralization were still actively progressing in the
tissue surrounding the particles. In the CERASORB®
M-group, bone formation and particle degradation had
already reached a more advanced stage.”
15CERASORB® & CERACELL® – 2008
Year Legend Literature Products
DENTISTRY
2008 DC Plenk H, Lederer J (2008): CERASORB®,
d CERASORB®: Materialkundliche Grundlagen und klinisch- CERASORB® M
histomorphologische Erfahrungen.
[CERASORB®: Material science and clinical-histomorphological
experiences.]
Zahn Krone, 2008, 5: 16–20. Article in German.
Comment:
“In both granulate forms of CERASORB®, a progredient
growth of woven bone around and in particular in the
granulates is to be seen (“creeping bony substitution”). Both
CERASORB® granulates are appropriate bone substitutes
which are replaced by own bone tissue in a unique way.”
CERASORB® & CERACELL® – 2007
Year Legend Literature Products
2007 DC Bilk D (2007): CERASORB® M,
d CERASORB® M in Dental Surgery – Post-marketing surveillance membrane
study with 148 patients.
EDI Journal 2007, 3 (4): 40–46.
Comment:
“Treatment assessments of the 148 patients performed after
3 and 6 months showed continuous decrease of
radiographically visible granulate, so that most implants
could be placed between 4 to 6 months. Handling, efficiency
and healing of the bone substitute were also assessed as
good and very good in the vast majority of cases.”
2007 DC Cramer A (2007): CERASORB®,
d Sinuslift und enossale Implantation. Eine retrospektive PRP,
Zehnjahresstudie. (membrane)
[Sinus elevation and endosseous implantation. A retrospective
10-years study.]
Dissertation an der Klinik und Poliklinik für Mund-, Kiefer- und
plastische Gesichtschirurgie, Hohe Medizinische Fakultät der
Rheinischen Friedrich-Wilhelms-Universität Bonn, Germany,
2007: 1–94. URN: urn:nbn:de:hbz:5M-09647. Text in German.
Comment:
“In 144 patients 213 sinus-lift operations were performed and
514 dental implants placed. The application of the synthetic
phase-pure β-tricalcium phosphate CERASORB® as bone
substitute leads to excellent results regarding the implant
survival rate.”
16CERASORB® & CERACELL® – 2007
Year Legend Literature Products
DENTISTRY
2007 DC Waluga R, Voigt A, Adolphs N, Nelson K, Klein M (2007): CERASORB® M
d Augmentation eines Unterkieferknochendefekts nach
Alveolarkammdistraktion. Die Anwendung von
β-Tricalciumphosphat (β-TCP).
[Augmentation of a mandible defect after alveolar ridge distraction
– use of β-tricalcium phosphate (β-TCP).]
Impl J 2007, 5: 28–32. Article in German.
Comment:
“In the context of a surveillance study, the use of β-TCP for
filling a larger mandibula defect after distraction-
osteogenesis is reported. Despite a defect volume of
4–5 ccm, β-TCP could be used with a good result even
without additional autologous spongiosa.”
CERASORB® & CERACELL® – 2006
Year Legend Literature Products
2006 DC Bilk D (2006): CERASORB® M,
d A New Bioresorbable Membrane in Augmentation Surgery. PRP,
Implants 2006, 1: 20–21. membrane
Comment:
“A new bioresorbable membrane (INION) in combination with
CERASORB® M and PRP enables the placement of implants
after sinus augmentation, even in cases where the residual
bone hight was to be considered borderline for single-stage
procedure.”
2006 DC Bilk D (2006): CERASORB® M,
d Eine neue resorbierbare Membran. PRP,
[A New Resorbable Membrane.] membrane
Implantologie Journal 2006, 1: 22–24. Article in German.
Comment:
“The augmentation was performed with a combination of
CERASORB® M, fresh blood and PRP covered by the
resorbable membrane INION. This procedure leads to good
bone regeneration after 6 months.”
17CERASORB® & CERACELL® – 2006
Year Legend Literature Products
DENTISTRY
2006 DC Cseplö K, Vaszilko M, Bogdan S, Barabas J, Suba Z, Szabo G CERASORB®
d (2006):
Use of β-tricalcium-phosphate (CERASORB®) to fill large
jawbone defects: a medium-term study.
Poster presentation, XV. ALACIBU-Congress in Cancun/Mexico,
01 May 2006.
Comment:
“17 large jawbone defects were filled with 3 – 10 g
CERASORB® mixed with blood taken from the bone defect.
After 36 – 60 months all bone defects healed uneventfully.
CERASORB® was almost completely resorbed and new bone
building had occurred.”
2006 DC Dominiak M, Łysiak K (2006): CERASORB®,
d Ocena skuteczności wybranej metody regeneracji kości z barrier,
zastosowaniem materiału wszczepialnego w leczeniu membrane,
poekstrakcyjnych ubytków kości wyrostka zębodołowego – PTFE
badania wstępne.
[Evaluation of Effectiveness of Selected Guide Bone
Regeneration Method with Usage Biomaterial in the Treatment of
the Defects of Alveolar Process After Teeth Extractions –
Preliminary Study.]
Dent. Med. Probl. 2006, 43, 3: 368–378. Article in Polish.
Abstract in English.
Comment:
“This study suggests that treatment of extraction sockets
with biomaterial (CERASORB®) and barrier membranes
(TefGen®) is valuable in preserving alveolar bone in
extraction sockets and preventing alveolar ridge defects.“
2006 DC Horch HH, Pautke C (2006): CERASORB®
d Regeneration statt Reparation – Eine kritische Bewertung des
autogenen Knochentransplantates als „Goldstandard” bei der
rekonstruktiven Chirurgie im Kieferbereich.
[Regeneration instead of reparation – A critical review of the
autogenous bone transplant as “golden standard” of
reconstructive oral surgery.]
Mund-, Kiefer- und GesichtsChir. 2006, 10 (4): 213–220.
Article in German.
Comment:
“Due to the further development of modern bone substitute
materials which reveal in part superior long-term results for
special indications the routine use of autogenous bone has
to be critically reviewed.”
18CERASORB® & CERACELL® – 2006
Year Legend Literature Products
DENTISTRY
2006 DC Horch HH, Sader R, Pautke C, Neff A, Deppe H, Kolk A (2006): CERASORB®
d Synthetic, pure-phase beta-tricalcium phosphate ceramic
granules (CERASORB®) for bone regeneration in the
reconstructive surgery of the jaws.
Int. J. Oral Maxillofac. Surg. 2006, 35: 708–713.
Comment:
“The aim of the study was to investigate the long-term effect
of the ceramic β-TCP at different sites of alveolar recon-
struction and to evaluate its properties in 152 patients up to
52 weeks postoperative. Complete radiological replacement
of β-TCP by autologous bone was found after approximately
12 months, indicating its osteoconductive properties.”
2006 DC Ormianer Z, Palti A, Shifman A (2006): CERASORB®
d Survival of Immediately Loaded Dental Implants in Deficient
Alveolar Bone Sites Augmented with β-Tricalcium Phosphate.
Implant Dentistry 2006, 15 (4): 395–403.
Comment:
“In all cases, bone defects were filled with β-tricalcium
phosphate (CERASORB®) and immediate loading was per-
formed with the goal of improving implant survival. After up
to 4 years of clinical follow-up 1039 implants (97%) survived.”
2006 DC Palm F (2006): CERASORB® M
d CERASORB® M – a new synthetic pure-phase β-TCP ceramic
material in oral and maxillofacial surgery – An open study of
121 patients.
IMOI 2006, 3: 24–27.
Comment:
“The results of this evaluation show CERASORB® M to be an
ideal synthetic material with a porosity concerning body’s
own spongiosa, degradation in time and simultaneous
formation of body’s own bone, which enables the placement
of implants already after 4–6 months.”
2006 DC Princ G, Bert M, Ifi JC (2006): CERASORB®
d Utilisation du substitut osseux β-phosphate tricalcique (β-TCP).
Résultats à 3 ans.
Le Chirurgien-Dentiste De France No. 1250/1251. 23–30 Mars
2006: 29–32.
Comment:
“From a study, which has been conducted with 72 patients, a
number of 10 patients could be examined after 3 years. The
results of the 3 years showed a good stability of all implants
as well clinically as well radiologically.”
19CERASORB® & CERACELL® – 2006
Year Legend Literature Products
DENTISTRY
2006 DC Schermer S (2006): CERASORB® M,
d Augmentation and Defect Reconstruction with a New Synthetic membranes,
Pure-Phase Beta-Tricalcium Phosphate – Open trial in Epi-Guide,
289 patients. PTFE
EDI Journal – European Journal for Dental Implantology 2006,
1: 31–39.
Comment:
“CERASORB® M is an ideal synthetic material for use in the
dental practice which does not expose surgeons and pa-
tients to the risk inherent in materials of biologic origin nor
does it require extensive pre-procedure patient information.”
2006 DC Schermer S (2006): CERASORB® M,
d Augmentation und Defektrekonstruktion mit einer neuen membranes,
synthetischen, phasenreinen β-TCP Keramik (CERASORB® M). Epi-Guide,
[Augmentation and Defect Reconstruction with a New Synthetic, PTFE
Pure-phase β-TCP Ceramic (CERASORB® M).]
Implantologie Journal 2006, 10 (2): 36–44. Article in German.
Comment:
“In an open evaluation with 289 patients CERASORB® M
showed to be an ideal synthetic material with a porosity
concerning body’s own spongiosa for use in the dental
practice.”
2006 DC Schermer S (2006): CERASORB®,
d Defektrekonstruktion mit alloplastischen Knochenersatzmaterialien CERASORB® M,
– Implantation bei reduziertem und stark reduziertem membranes,
Knochenangebot. Epi-Guide,
[Defect Reconstruction with Alloplastic Bone Substitute Materials PTFE
– Implantations in reduced and severely reduced Bone.]
Oralchirurgie Journal 2006, 1: 22–26. Article in German.
Comment:
“With the β-TCP materials CERASORB® and CERASORB® M,
materials with highest phase-purity are available, which
proved their value in the daily practice as well in common
situations as well in difficult indications.”
2006 DC Schermer S (2006): CERASORB®,
d Einzeitige Sofort- oder zweizeitige Spät-Insertion von CERASORB® M,
3i-Implantaten in rekonstruierten oder zu rekonstruierenden membranes,
Arealen. Epi-Guide,
[Immediate or delayed insertion of 3i-implants in reconstructed or PTFE
to be reconstructed areas] Implantologie Journal 2006, 4 (10):
42–47. Article in German.
Comment:
“CERASORB®, CERASORB® M respectively, showed after
3 – 6 months regularly a good resorption and in relation to
time and the individual situation of the patient a very good
osseointegration of the dental implants.”
20CERASORB® & CERACELL® – 2006
Year Legend Literature Products
DENTISTRY
2006 DC Suba Z, Takacs D, Matusovits D, Barabas J, Fazekas A, Szabo G CERASORB®
d (2006):
Maxillary sinus floor grafting with β-tricalcium phosphate in
humans: density and microarchitecture of the newly formed bone.
Clin. Oral Impl. Res. 2006, 17: 102–108.
Comment:
“In 17 edentulous patients, the maxilla sinus floor was
extremely atrophied, which was surgically elevated
bilaterally by insertion of CERASORB® or autogenous bone
graft. After 6 months, the new bone density was not
significantly different. The augmented sinus floor was strong
and suitable for anchorage of dental implants.”
2006 DC Szabo G, Bogdan S, Suba Z, Martonffy K, Hrabak K, Barabas J CERASORB®
d (2006):
Füllung großer Kieferknochendefekte mit β-Tricalciumphosphat
(CERASORB®): Eine Fünfjahresstudie.
[Filling of large jawbone defects with β-tricalciumphosphate
(CERASORB®): A five-year study.]
Z Oral Implant 2006, 4: 202–211. Article in German.
Comment:
“14 patients with 18 large defects of a diameter over 4 cm
were observed over 5 years. In all cases, the filling with pure
β-TCP CERASORB® was sufficient for a complete biological
remodelling.”
CERASORB® & CERACELL® – 2005
Year Legend Literature Products
2005 DC Bilk D (2005): CERASORB®,
d Vorhersehbare und sichere Knochenregeneration mit CERASORB® M,
verschiedenen Formen eines phasenreinen β-Tricalciumphosphats. membranes,
[Predictable and Safe Bone Regeneration with Different Forms of Epi-Guide,
a Pure-phase β-Tricalciumphosphate.] PTFE,
Dent Implantol 2005, 9 (7): 564–572. Article in German. (PRP)
Comment:
“A procedure concerning the protocol forms an aug-
mentation complex from the synthetic inorganic material
with which even large bony defects can be treated success-
fully and implants can be placed immediately or promptly.”
21CERASORB® & CERACELL® – 2005
Year Legend Literature Products
DENTISTRY
2005 DC Hille R (2005): CERASORB®,
d Alveolar Ridge Preservation: Knochenaufbau nach Extraktion. barriers,
[Alveolar Ridge Preservation: Bone Regeneration after membranes,
Extraction.] Epi-Guide,
Implantologie Journal 2005, 1: 12–18. Article in German. PTFE
Comment:
“The resorption of the alveolar bone after extraction of teeth
is considerably less due to simultaneous augmentation of
the alveoli with CERASORB® and the use of non-resorbable
(TefGen) or resorbable (Epi-Guide) membranes as barriers
on the extraction alveolus. The tolerability of the described
procedures and materials is clinically evaluated as good to
very good. Thus, this method can be recommended if a maxi-
mum preservation of the alveolar bone is essential,
particularly for prosthetic reconstructions or because of
aesthetic reasons.”
2005 DC Hille R, Vollmer R (2005): CERASORB®,
d Alveolar Ridge Preservation: Preserving and Building up the membranes,
Bony Structures after Extraction. Epi-Guide,
Implants – International Magazine of Oral Implantology, Vol. 6 PTFE
2005, 1: 22–28.
Comment:
“In a field study it could be shown that after the application
of CERASORB® and of an appropriate membrane technique
the alveolar crest could be maintained.“
2005 DC Hoch T (2005): CERASORB®,
d Klinische Anwendung von Knochenaufbaumaterial bei PRP,
Implantation mit offener Einheilung. membranes,
[Clinical Application of Bone Substitutes at Dental Implantation PTFE
with open Wound Healing] Implantologie Journal 2005, 4: 6–8.
Article in German.
Comment:
“CERASORB® used mixed with blood and in combination
with PRP or different membranes proves to be a bone
augmentation material which is easy to use and shows high
compatibility as well as safety regarding bone quality in the
augmentation area.”
2005 DC Motsonelidze NR, Okropiridze TV, Kapanadze RV (2005): CERASORB®
d [Usage of CERASORB® in Complex Treatment of Chronic
Generalized Periodontitis (Clinical-Experimental Study)].
Georgian Medical News, DUP-General Collection, W1 GE454n,
No. 1, Jan. 2005, 17–20. Article in Russian.
Comment:
“CERASORB® was used in the treatment of chronic
generalized periodontitis. After 18 months the bone
regeneration, confirmed by radiography, was shown in 87.8%
and only 60.1% in the control group. CERASORB® can be
recommended for using in the clinical practice.”
22CERASORB® & CERACELL® – 2005
Year Legend Literature Products
DENTISTRY
2005 DC Palti A, Hermann F (2005): CERASORB®
d Die geschlossene Sinusbodenelevation. Eine retrospektiv-
röntgenologische Studie auf der Basis von 204 Implantaten zur
Beurteilung der Veränderung der erzielten Augmentationshöhe.
[Closed sinus floor augmentation. A retrospective radiological
study based on 204 implants to evaluate the change of the
achieved augmentation height.]
Z Oral Implant 2005, 1: 6–14. Article in German.
Comment:
“Sinus floor elevation has been performed in 104 patients,
radiological follow-up was up to 24 months. An aug-
mentation height of 2–4 mm could be reached in 44.1%, of
4–6 mm in 35.3% of the patients. The survival rate of all
controlled implants was 96.1% within 2 years.”
2005 DC Plenk H jr, Lederer J (2005): CERASORB®,
d Histomorphologie der Knochenregeneration nach CERASORB® M
Sinusbodenaugmentation mit zwei Formen eines TCP-Granulates
– ein Fallbericht.
[Histomorphology of the bone regeneration after sinus floor
augmentation with two different designs of TCP-granulates –
A case report.]
Z Oral Implant 2005, 1: 32–38. Article in German.
Comment:
“In a multiphase denture reconstruction CERASORB® and
CERASORB® M were used in sinus floor elevation. After
4.5 months growth of new built bone was seen between the
granules and on the outer and inner surface as well as a
smooth transition of the granulate to matrix of woven bone
tissue.”
2005 DC Reich R, Appel T, Martini M, Lückerath W (2005): CERASORB®
d Improvement of Implant Survival in Sinus Grafts by the Use of
Alloplastic Bone Replacement Materials.
2nd World Congress on Regenerative Medicine, Leipzig, Germany,
2005.
Comment:
“210 sinus grafts were performed in 188 patients and
494 implants placed in the region of interest. When used
β-TCP alone or in combination with autologous bone implant
survival rates were up to 98%. Resonance frequency
analysis delivered identical osseointegration levels for these
areas as obtained in implants placed in local D2 bone.”
23CERASORB® & CERACELL® – 2005
Year Legend Literature Products
DENTISTRY
2005 DC Szabo G, Huys L, Coulthard P, Maiorana C, Garagiola U, CERASORB®
d Barabas J, Nemeth Z, Hrabak K, Suba Z (2005):
A Prospective Multicenter Randomized Clinical Trial of
Autogenous Bone Versus β-Tricalcium Phosphate Graft Alone for
Bilateral Sinus Elevation: Histologic and Histomorphometric
Evaluation.
Int J Oral Maxillofac Implants 2005, 20: 371–381.
Comment:
“Bilateral sinus grafting was performed on 20 patients.
CERASORB® only was used on the experimental side, and
autogenous bone only on the control side. Histologically and
histomorphometrically, there was no significant difference
between CERASORB® and autogenous bone in terms of
quantity and rate of ossification.”
2005 DC Szabo G, Barabas J, Hrabak K, Suba Z, Garagiola U, Kadar B CERASORB®
d (2005):
Autologer Knochen versus β-Tricalcium-Phosphat allein –
Eine radiologische und histologische Evaluation.
[Autologous bone versus β-tricalcium phosphate alone –
a radiological and histological evaluation.]
Z Oral Implant 2005, 4 (1): 216–222. Article in German.
Comment:
“Bilateral sinus grafting was performed simultaneously –
β-TCP (CERASORB®) randomly on one side, autogenous
bone on the other side. The implants were placed after 6
months: The formation of new bone was similar on both
sides.”
2005 DC Szabo G, Barabas J, Nemeth Z, Hrabak K, Suba Z (2005): CERASORB®
d Vergleich von autologem Knochen mit β-Tricalciumphosphat bei
bilateralem Sinuslift.
[Comparison of autologous bone with β-tricalciumphosphate in
bilateral sinus lift.]
Implantologie Journal 2005, 6: 50–53. Article in German.
Comment:
“The new bone production was similar on both sides. The
difference between the two sides was not significant. These
results support the view that β-TCP can be a satisfactory
graft material even without the addition of autogenous
bone.”
2005 DC Wainwright M (2005): CERASORB® M,
d Augmentation unter besonderer Berücksichtigung der Ästhetik. membrane,
Zwei unterschiedliche Verfahren im Vergleich. PTFE
[Augmentation in special consideration of aesthetics. Two
different procedures in comparison.]
Implantologie Journal 2005, 4: 18–21. Article in German.
Comment:
“To achieve a perfect restoration, “ridge-preservation-
technique” is performed with β-TCP CERASORB® M and a
non-resorbable membrane (TefGen). The implants are placed
after 4–5 months – after the loss of a single tooth as well as
after the loss of a number of teeth in the front tooth region.”
24CERASORB® & CERACELL® – 2005
Year Legend Literature Products
DENTISTRY
2005 DC Zerbo IR, Bronckers AL, de Lange G, Burger EH (2005): CERASORB®
d Localisation of osteogenic and osteoclastic cells in porous
β-tricalcium phosphate particles used for human maxillary sinus
floor elevation.
Biomaterials 26 (2005): 1445 –1451. doi:10.1016/j.
biomaterials.2004.05.003.
Comment:
“In conclusion, this study confirms the hypothesis based on
our earlier work that the cells infiltrating around and within
the TCP material are osteogenic. The data suggest that the
mechanism of degradation of the material is likely to be due
to chemical dissolution and that the role played by
osteoclasts is only minor.”
2005 DC Zijderveld SA, Zerbo IR, van den Bergh JP, Schulten EA, CERASORB®
d ten Bruggenkate CM (2005):
Maxillary Sinus Floor Augmentation Using a β-Tricalcium
Phosphate (CERASORB®) Alone Compared to Autogenous Bone
Grafts.
Int J Oral Maxillofac Implants 2005, 20 (3): 432–440.
Comment:
“The results of the present study show that the sinus floor
elevation procedure with β-TCP appears to be a reliable two
phase procedure. Within the one year of follow-up no implant
losses or failures had occurred.”
CERASORB® & CERACELL® – 2004
Year Legend Literature Products
2004 DC Basa S, Varol A, Turker N (2004): CERASORB®,
d Alternative Bone Expansion Technique for Immediate Placement PRP
of Implants in the Edentulous Posterior Mandibular Ridge: A
Clinical Report.
Int J Oral Maxillofac Implants 2004 Jul–Aug, 19 (4): 554–558.
Comment:
“The split-crest surgical technique is a valid reconstructive
procedure for sharp posterior mandibular ridges. If
performed using platelet-rich plasma and CERASORB®, it
can shorten the osseointegration period.”
25CERASORB® & CERACELL® – 2004
Year Legend Literature Products
DENTISTRY
2004 DC Bilk D (2004): CERASORB®,
d Die Implantatversorgung außergewöhnlicher Defektsituationen. membrane,
[Implant placement in exceptional defect situations.] PTFE
Implantologie Journal 2004, 2: 30–36. Article in German.
Comment:
“The case descriptions show that today with modern augmen-
tation and membrane techniques (CERASORB®, TefGen®-
membrane) it is possible to treat even extreme cases without
putting too much strain on the patient but effective and suc-
cessful, without additional and unnecessary risks by
additional operations.”
2004 DC Broos B (2004): CERASORB®,
d Unterstützende Maßnahmen beim internen Sinuslift zum Schutz stypro®
der Kieferhöhlenschleimhaut (Schneidersche Membran).
[Supporting measures to protect the Schneiderian membrane in
internal sinus lift operations.]
Implantologie Journal 2004, 7: 47–48. Article in German.
Comment:
“After the preparation of the Schneiderian membrane with
special osteotomes a gelatine sponge (stypro®) is inserted
followed by the augmentation with pure-phase β-tricalcium
phosphate CERASORB®. This procedure protects the
Schneiderian membrane and improves the healing process.
No complications have been observed.”
2004 DC Hoch D (2004): CERASORB®
d Verkleinerung von Ohrradikaloperationshöhlen mit phasenreiner
β-Trikalziumphosphatkeramik.
[Reduction of radical ear surgery cavities with pure-phase
β-tricalcium phosphate.]
Dissertation, Ruhr-University Bochum, Germany 2004, 1–70.
Text in German.
Comment:
“The histologic specimen show a large zone of newly formed
bone. In those areas, which are not filled with newly built bone
so far, β-tricalcium phosphate CERASORB® has the function
of a placeholder serving as a scaffold and guide rail for the
bone regeneration. … 37 patients (86% success rate) were
free of symptoms. Thus the aim of treatment was reached …”
2004 DC Hotz W (2004): CERASORB®,
d Retrospektive Fallstudie zum Sinuslift mit CERASORB® und PRP. PRP,
[Retrospective Case Study – Sinus Lift with CERASORB® and membranes
PRP.] Implantologie Journal 2004, 1: 20–27. Article in German.
Comment:
“Augmentation with the bone regeneration material
CERASORB®, with and without addition of PRP, is a
convenient and reliable method for both the dental
implantologist and his patients, where an adequate implant
bed is created from vital autologous bone within a
reasonable amount of time.”
26You can also read
